Teva- Pharmaceutical Industries Ltd

NYSE: TEVA
$17.11
-$0.39 (-2.2%)
Closing Price on November 8, 2024

TEVA Articles

The August 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks was mixed.
The FDA is extending the expiration dates for certain EpiPens in light of the national shortage ahead of the back-to-school season.
Mylan has had a stranglehold on the market for EpiPen, but this is all changing after the FDA approved Teva for a generic version of it.
Teva and Regeneron both saw handy gains on Thursday after the companies posted positive topline results from their late-stage trial of fasinumab in patients with chronic pain from osteoarthritis...
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The top analyst upgrades, downgrades and other research calls from Friday include Blue Apron, Energy Transfer Partners, Funko, Symantec, Tesla, Teva Pharmaceutical and TripAdvisor.
Teva shares stumbled after it released its most recent quarterly results before the markets opened on Thursday.
The July 13 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The June 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The June 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The top analyst upgrades, downgrades and other research calls from Wednesday include AT&T, Abbott Laboratories, Honeywell, Tiffany and Zimmer Biomet.
Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.
The May 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The top analyst upgrades, downgrades and other research calls from Thursday include Broadcom, Deere, Generac, McDermott, NetApp, NRG Energy, Petrobras, Teva Pharmaceutical and Tiffany.
Amgen shares saw a nice bump after the FDA on Thursday approved its preventive treatment of migraine in adults.